Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cancer cell lines

Prostate

Volumn 31, Issue 2, 1997, Pages 77-83

  De Vos, Sven ^a   Holden, Stuart ^a   Heber, David ^b   Elstner, Elena ^a   Binderup, Lise ^d   Uskokovic, Milan ^e   Rude, Bob ^c   Chen, Dan Lin ^a   Le, Jennifer ^a   Cho, Steve K ^a   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOINT REPLACEMENT INSTITUTE   (United States)

^d Orthopedics Hospital ^*  (Denmark)

^e HOFFMANN LA ROCHE INC   (United States)

Author keywords

colony assay; growth inhibition; hypercalcemia; prostate cancer; vitamin D3 analogs

Indexed keywords

1,25 DIHYDROXY 16 ENE VITAMIN D3; 9,10 SECOCHOLESTA 5,7,10(19),16 TETRAEN 23 YNE 1,3,25 TRIOL; CALCIUM; COLECALCIFEROL DERIVATIVE; LEXACALCITOL; SEOCALCITOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM BLOOD LEVEL; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; HUMAN; HUMAN CELL; HYPERCALCEMIA; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0031003924     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19970501)31:2<77::AID-PROS1>3.0.CO;2-E     Document Type: Article

References (37)

1. Boring CC, Squires TS, Tong T: Cancer statistics, 1991. CA Cancer J Clin 41:19-36, 1991.
2. Carter HB, Coffey DS: Prostate cancer: The magnitude of the problem in the United States. In Coffey DS, Resnick MI, Dorr FA, Karr JP (eds): "A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer." New York: Plenum Publishing Corp., 1988, pp 1-7.
3. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952-1960, 1994.
4. 3 on primary cultures of prostatic cells. Cancer Res 54:805-810, 1994.
5. 3 in controlling breast cancer cell proliferation. Lancet 1:188-191, 1989.
6. 3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci USA 80:201-204, 1983.
7. 3 on metastasis of rat ascites hepatoma K-231. Br J Cancer 50:123-125, 1984.
8. 3. Cancer Res 47:21-25, 1987.
9. Bower M, Colston KW, Stein RC, Hedley A, Gazet J-C, Ford HT, Combes RC: Topical calcipotriol treatment in advanced breast cancer. Lancet 337:701-702, 1991.
10. 3. Proc Natl Acad Sci USA 79:4990-4994, 1981.
11. 3 induces differentiation of human myeloid leukemia cells. Biochem Biophys Comm 102:937-943, 1981.
12. Olsson J, Gullberg U, Ivhed I, Nilsson K: Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1 alpha,25-dihydroxycholcalciferol. Cancer Res 43:5862-5867, 1983.
13. 3 receptor. Cancer Res 44:2103-2109, 1984.
14. 3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): Receptor-mediated maturation to macrophage-like cells. J Cell Biol 98:391-398, 1984.
15. 3 metabolites on normal and leukemic bone marrow cells in vitro. Int J Cell Cloning 2:227-242, 1984.
16. 3 and its fluorinated analogs. Cancer Res 44:5624-5628, 1984.
17. 3: In vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 69:1399-1407, 1985.
18. Munker R, Norman AW, Koeffler HP: Vitamin D compounds: Effect on clonal proliferation and differentiation of human myeloid cells. J Clin Invest 78:424-430, 1986.
19. 3 on the morphology of human breast cancer cell line BT20. Differentiation 40:63-69, 1989.
20. 3: Differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption. Cancer Res 50:6857-6864, 1990.
21. 3 prolongs survival of leukemic mice. Proc Natl Acad Sci USA 87:3929-3933, 1990.
22. 3 analogs: Effect on leukemic clonal growth differentiation and serum calcium. Leuk Res 19:65-71, 1995.
23. 3: An extraordinarily potent inhibitor of leukemic cell growth in vitro. Blood 84:1960-1967, 1994.
24. 3 analogs: A novel class of potent inhibitors of proliferation and inducer of differentiation of human breast cancer cell lines. Cancer Res 55:2822-2830, 1995.
25. 3 is a potent anileukemic agent with low potential to cause hypercalcemia. Leuk Res 18:453-463, 1994.
26. 3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res 282:164-167, 1990.
27. Binderup L, Latini S, Binderup E, Bretting C, Calverley M, Hansen K: 20-Epi-vitamin D3 analogues: A novel class of potent regulators of cell growth and immune responses. Biochem Pharmacol 42:1569-1575, 1991.
28. Anzano MA, Smith JM, Uskokovic MC, Peer CW, Mullen LT, Letterio JJ, Welsh MC, Shrader MW, Logsdon DL, Driver CL, Brown CC, Roberts AB, Sporn MB: 1 Alpha,25-dihydroxy-16-ene-23yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res 54:1653-1656, 1994.
29. 3: Preferential activity in inducing differentiation of human leukemia cells HL-60 in vitro. Proc Natl Acad Sci USA 84: 2610-2614, 1987.
30. 3 with an oxygen atom in the side chain skeleton. A trial of the development of vitamin D compounds which exhibit potent differentiation-inducing activity without inducing hypercalcemia. FEBS Lett 226:58-62, 1987.
31. Binderup L, Bramm E: Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 37:887-895, 1988.
32. Colston KW, Mackay AG, James SY, Binderup L, Chander S, Coombes RC: EB1089: A new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol 44:2273-2280, 1992.
33. Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR: Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs. Anticancer Res 14:1077-1082, 1994.
34. Kaighn ME, Lechner JF, Narayan KS, Jones LW: Prostate carcinoma: Tissue culture cell lines. Mongr Natl Cancer Inst 49:17-21, 1978.
35. Mickey DD, Stone KR, Wunderli H, Mickey GH, Paulson DF: Characterization of a human prostate adenocarcinoma cell line (DU 145) as a monolayer culture and as a solid tumor in athymic mice. Prog Clin Biol Res 37:67-84, 1980.
36. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res 43:1809-1818, 1983.
37. Bouillon R, Okamura W, Norman AW: Structure-function relationship in the vitamin D endocrine system. Endocr Rev 16:200-257, 1995.